Are two binding sites better than one?
A new study using x-ray crystallography has shown that the investigational agent matuzumab binds to EGFR at a different site than cetuximab (Erbitux).
PHILADELPHIA-A new study using x-ray crystallography has shown that the investigational agent matuzumab binds to EGFR at a different site than cetuximab (Erbitux). Their binding does not overlap, and they can bind to EGFR at the same time, Kathryn Ferguson, PhD, of the University of Pennsylvania School of Medicine, reported in Cancer Cell (13:365-373, 2008). The finding suggests the possibility of a new combination therapy for certain types of cancer, including colorectal cancer. Matuzumab is being developed by Merck KGaA.
Articles in this issue
Immunotherapy agent promising in NSCLC
NCCN greenlights nilotinib for imatinib-resistant CML patients
No overall survival benefit for dose-intense regimen in SCLC
Make a note of new smoking cessation codes
Relistor for treating OIC
Experts argue against need for phase III proton Rx trials
Spotlight on Cancer Centers
Novel peptide vaccine promising in myeloid leukemia
Masters of hematology and oncology: Father of tamoxifen a Brit to the core
Intensive imatinib/chemo ups EFS in pediatric Ph+ ALL
Relapsing DLBCL patients respond to rituximab-based Rx
Who’s News
From the Editor
New compound inhibits Src family kinases
Are two binding sites better than one?
Recent Videos
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
